Seviteronel in Combination With Chemotherapy in Androgen-receptor Positive Metastatic Triple-negative Breast Cancer

Trial Details

NCT ID

NCT04947189

Phase

PHASE1 / PHASE2

Sponsor

St Vincent's Hospital, Sydney

Status

RECRUITING

Cancer Type

Breast Cancer

Interventions

• Seviteronel-D (Seivteronel in combination with dexamethasone)
• Docetaxel

Locations (sample)

• Darlinghurst, New South Wales, Australia|-33.87939,151.21925

Key Eligibility Criteria

• Signed written and voluntary informed consent.
• Patient must be willing and able to comply with scheduled visits, treatment plan, laboratory tests and other study procedures.
• Age 18 years or older male or female.
• Eastern Cooperative Oncology Group Performance Status of 0 or 1

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.